Biocryst Pharmaceuticals Inc (BCRX) financials

Biocryst Pharmaceuticals Inc (BCRX) revenue, EBIT and EBITDA, earnings per share, free cash flow, margins, debt and shareholders equity — annual and quarterly history, charted from SEC filings. No account needed.

In fiscal 2025, Biocryst Pharmaceuticals Inc reported revenue of $875M, up 94.1% year over year, net income of $264M, diluted EPS of $1.21 and free cash flow of $345M.

Revenue (fiscal 2025)

$875M

Revenue growth (fiscal 2025)

94.1%

Net income (fiscal 2025)

$264M

Diluted EPS (fiscal 2025)

$1.21

Free cash flow (fiscal 2025)

$345M

Biocryst Pharmaceuticals Inc files with the U.S. Securities and Exchange Commission under CIK 0000882796, classified as Biological Products, (No Diagnostic Substances).

Explore annual and quarterly revenue, earnings, cash flow, margins, debt and equity from SEC filings.